Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 0.2% - What's Next?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report)'s stock price was down 0.2% during trading on Friday . The company traded as low as $8.90 and last traded at $8.90. Approximately 33,040 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 46,134 shares. The stock had previously closed at $8.92.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their target price on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a research report on Monday, April 21st.

Greenwich LifeSciences Trading Down 0.2%

The company's 50 day moving average price is $9.59 and its two-hundred day moving average price is $11.12. The firm has a market cap of $118.99 million, a PE ratio of -7.06 and a beta of 1.69.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). Equities research analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Insider Activity at Greenwich LifeSciences

In related news, CEO Snehal Patel purchased 3,600 shares of the firm's stock in a transaction on Friday, April 25th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $35,568.00. Following the purchase, the chief executive officer now directly owns 5,570,602 shares in the company, valued at $55,037,547.76. This trade represents a 0.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have bought 18,100 shares of company stock worth $164,835. 51.67% of the stock is owned by corporate insiders.

Institutional Trading of Greenwich LifeSciences

Several hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its stake in Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after purchasing an additional 1,008 shares in the last quarter. Barclays PLC lifted its stake in Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company's stock worth $108,000 after purchasing an additional 1,088 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Greenwich LifeSciences in the 1st quarter worth $126,000. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Greenwich LifeSciences by 15.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock worth $181,000 after buying an additional 2,552 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.